NCT00002949View on ClinicalTrials.gov

Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 31, 1996

Primary Completion Date

November 30, 2000

Study Completion Date

May 31, 2001

Conditions
Bladder CancerCervical CancerEndometrial CancerVaginal Cancer
Interventions
DRUG

paclitaxel

Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)

DRUG

vinorelbine tartrate

Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2),

RADIATION

radiation therapy

Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy)

Trial Locations (1)

60637

University of Chicago Cancer Research Center, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT00002949 - Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis | Biotech Hunter | Biotech Hunter